Gilead Sciences, Inc. (GILD)
NASDAQ: GILD · Real-Time Price · USD
139.71
-0.59 (-0.42%)
At close: Apr 2, 2026, 4:00 PM EDT
139.89
+0.18 (0.13%)
After-hours: Apr 2, 2026, 7:57 PM EDT
Gilead Sciences Employees
Gilead Sciences had 17,000 employees as of December 31, 2025. The number of employees decreased by 600 or -3.41% compared to the previous year.
Employees
17,000
Change (1Y)
-600
Growth (1Y)
-3.41%
Revenue / Employee
$1,731,941
Profits / Employee
$500,588
Market Cap
173.41B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 17,000 | -600 | -3.41% |
| Dec 31, 2024 | 17,600 | -400 | -2.22% |
| Dec 31, 2023 | 18,000 | 1,000 | 5.88% |
| Dec 31, 2022 | 17,000 | 2,600 | 18.06% |
| Dec 31, 2021 | 14,400 | 800 | 5.88% |
| Dec 31, 2020 | 13,600 | 2,600 | 23.64% |
| Jan 31, 2019 | 11,000 | 1,000 | 10.00% |
| Jan 31, 2018 | 10,000 | 1,000 | 11.11% |
| Jan 31, 2017 | 9,000 | 1,000 | 12.50% |
| Jan 31, 2016 | 8,000 | 1,000 | 14.29% |
| Jan 31, 2015 | 7,000 | 900 | 14.75% |
| Jan 31, 2014 | 6,100 | 1,100 | 22.00% |
| Jan 31, 2013 | 5,000 | 500 | 11.11% |
| Jan 31, 2012 | 4,500 | 500 | 12.50% |
| Jan 31, 2011 | 4,000 | 148 | 3.84% |
| Jan 31, 2010 | 3,852 | 411 | 11.94% |
| Jan 31, 2009 | 3,441 | 462 | 15.51% |
| Jan 31, 2008 | 2,979 | 464 | 18.45% |
| Jan 31, 2007 | 2,515 | 615 | 32.37% |
| Jan 31, 2006 | 1,900 | 246 | 14.87% |
| Feb 28, 2005 | 1,654 | 229 | 16.07% |
| Feb 27, 2004 | 1,425 | 175 | 14.00% |
| Feb 28, 2003 | 1,250 | 250 | 25.00% |
| Feb 28, 2002 | 1,000 | 150 | 17.65% |
| Feb 28, 2001 | 850 | 90 | 11.84% |
| Dec 31, 1999 | 760 | 467 | 159.39% |
| Dec 31, 1998 | 293 | 4 | 1.38% |
| Dec 31, 1997 | 289 | 41 | 16.53% |
| Dec 31, 1996 | 248 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Johnson & Johnson | 138,200 |
| AstraZeneca | 95,100 |
| Novartis AG | 75,267 |
| Pfizer | 75,000 |
| Merck & Co. | 75,000 |
| Sanofi | 74,846 |
| Novo Nordisk | 69,505 |
| GSK plc | 66,841 |
GILD News
- 1 day ago - Gilead Extends Tender Offer to Acquire Arcellx - Business Wire
- 1 day ago - Markets Haven't Changed. These 2 Cheap Dividends Still Rule - Forbes
- 2 days ago - Gilead Sciences, Inc. (GILD) M&A Call Transcript - Seeking Alpha
- 9 days ago - Gilead to Buy Ouro Medicines for $2.2 Billion. ‘Immune Reset' Is Key to Future Gains. - Barrons
- 10 days ago - Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion - WSJ
- 10 days ago - Gilead to buy biotech firm Ouro Medicines in over $2 billion deal - Reuters
- 10 days ago - Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases - Business Wire
- 10 days ago - Gilead nearing up to $2 billion buyout of biotech Ouro Medicines, FT reports - Reuters